This exploratory trial will have two parts. While Part A will focus on the safety evaluations, vaccine-induced immune responses (specifically neutralizing antibodies) will also be analyzed to assess if there is a dose-response. Part B of the trial will expand the safety characterization for a BNT163 dose selected based on Part A data and enable a more comprehensive assessment of the impact of pre-existing immunity to Herpes Simplex Virus (HSV)-1 and -2 on the safety and BNT163-induced immune responses after one selected (higher) dose of BNT163 than could be done during the dose escalation performed in Part A.
10 Primary · 3 Secondary · Reporting Duration: From day 1 up to day 337
Experimental Treatment
108 Total Participants · 2 Treatment Groups
Primary Treatment: BNT163 · Has Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Age 18 - 54 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:North Carolina | 42.9% |
Washington | 14.3% |
Massachusetts | 14.3% |
Other | 28.6% |
Accellacare Raleigh Medical Group | 100.0% |
Met criteria | 100.0% |
0 | 25.0% |
1 | 75.0% |
100.0% | |